Skip to content
HowShorted

Avid Bioservices, Inc. short interest in 2024

In 2024, Avid Bioservices, Inc.'s disclosed short interest ran from 8.76% of shares outstanding on 12 Jan 2024 to 17.50% on 31 Dec 2024, a change of +8.74 percentage points. The year's high was 23.75% on 14 Jun 2024 and its low 8.27% on 31 Jan 2024, averaging 17.39% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 30.22 days on 31 Oct 2024. Full history: Avid Bioservices, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for Avid Bioservices, Inc. in 2024

2024 in figures

Start of year
8.76% (12 Jan 2024)
End of year
17.50% (31 Dec 2024)
Change
+8.74 pp
High
23.75% (14 Jun 2024)
Low
8.27% (31 Jan 2024)
Average
17.39%
Highest days to cover
30.22 (31 Oct 2024)
SEC filings marked
9

Every report in 2024

Avid Bioservices, Inc. short interest in 2024
SettlementShort interestDays to coverFilings since previous
12 Jan 20248.76%5.42
31 Jan 20248.27%5.59
15 Feb 20248.93%5.69
29 Feb 202410.43%7.37
15 Mar 202417.14%3.77results (8-K)
28 Mar 202415.99%9.07
15 Apr 202416.26%10.49
30 Apr 202417.42%10.3210-Q filed, results (8-K)
15 May 202418.69%9.72
31 May 202418.13%14.28
14 Jun 202423.75%18.37
28 Jun 202419.44%10.00
15 Jul 202419.36%11.9010-K filed, results (8-K)
31 Jul 202421.90%9.69
15 Aug 202420.25%14.81
30 Aug 202420.37%24.49
13 Sep 202419.71%13.4210-Q filed, results (8-K)
30 Sep 202419.94%10.65
15 Oct 202420.68%21.78
31 Oct 202421.17%30.22
15 Nov 202418.37%1.93
29 Nov 202418.24%7.16
13 Dec 202416.74%10.4110-Q filed, results (8-K)
31 Dec 202417.50%10.71

See also: Avid Bioservices, Inc.'s full history · most shorted US stocks of 2024 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.